Mitral valve-in-ring (MViR) procedures performed via transseptal access show lower-than-expected 30-day mortality rates, making this a reasonable alternative for high-surgical-risk patients, according to late-breaking trial results presented Wednesday at Transcatheter Valve Therapies 2021 in Miami Beach, Florida.